Skip to main content
Erschienen in: Head and Neck Pathology 4/2022

06.07.2022 | Original Paper

Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?

verfasst von: Lisa M. Rooper, Jeffrey Gagan, Justin A. Bishop

Erschienen in: Head and Neck Pathology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Salivary duct carcinoma with rhabdoid features (SDC-RF) is a recently-described salivary gland tumor that bears striking histologic similarity to lobular carcinoma of the breast. While this tumor has an apocrine phenotype that supports classification as a variant of SDC, it infrequently arises in association with conventional SDC. Furthermore, discohesive architecture can be seen in non-apocrine salivary carcinomas, raising the possibility that discohesive growth should define a separate entity. In this study, we aimed to perform comprehensive molecular profiling of SDC-RF to better understand its pathogenesis and classification.

Methods

We documented the clinicopathologic features of 9 cases of SDC-RF and performed immunostains including AR, GCDFP, and e-cadherin on all cases. We also performed targeted next generation sequencing (NGS) panels on 7 cases that had sufficient tissue available.

Results

The SDC-RF represented 8 men and 1 woman with a median age of 67 years (range 63–83 years) and included 6 parotid, 2 buccal, and 1 submandibular primary. All tumors were uniformly composed of discohesive cells with abundant eosinophilic cytoplasm; signet-ring cell features were seen in 2 cases. All tumors were also positive for AR (100%) and GCDFP (100%), and 7 tumors (78%) displayed lost or abnormal e-cadherin. NGS highlighted concomitant PIK3CA and HRAS mutations in 4 tumors, with additional cases harboring TP53, PTEN, and AKT1 mutations. Furthermore, CDH1 alterations were seen in 6 cases, including a novel CDH1::CORO7 fusion. Among 5 patients with follow-up available, 3 (60%) developed local recurrence and widespread distant metastasis and died of disease at a median 20 months (range 10–48 months).

Conclusions

Overall, our findings confirm frequent CDH1 mutations and e-cadherin inactivation in SDC-RF, similar to discohesive tumors from other sites. We also highlight an apocrine molecular profile similar to conventional SDC. However, occasional AKT1 mutation and signet-ring features suggest SDC-RF may also be related to mucinous adenocarcinoma. As more salivary tumors with discohesive growth are identified, it may become clearer whether SDC-RF should remain in the SDC family or be recognized as a separate entity.
Literatur
1.
Zurück zum Zitat Kleinsasser O, Klein HJ, Hubner G. [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100–5.CrossRef Kleinsasser O, Klein HJ, Hubner G. [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1968;192(1):100–5.CrossRef
2.
Zurück zum Zitat Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77(2):223–30.CrossRef Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77(2):223–30.CrossRef
3.
Zurück zum Zitat Brandwein-Gensler MS, Skalova A, Nagao T. Salivary duct carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D. International Agency for Research on Cancer., editor. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Lyon: IARC; 2005. pp. 236–7. Brandwein-Gensler MS, Skalova A, Nagao T. Salivary duct carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D. International Agency for Research on Cancer., editor. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Lyon: IARC; 2005. pp. 236–7.
4.
Zurück zum Zitat Nagao T, Licitra L, Loening T, Vielh P, Williams MD. Salivary duct carcinoma. In: El-Naggar A, Chan JK, Grandis JR, Takata T, Slootweg PJ, editors. WHO Classification of Head and Neck Tumours. Lyon: International Agency for Research on Cancer; 2017. pp. 173–4. Nagao T, Licitra L, Loening T, Vielh P, Williams MD. Salivary duct carcinoma. In: El-Naggar A, Chan JK, Grandis JR, Takata T, Slootweg PJ, editors. WHO Classification of Head and Neck Tumours. Lyon: International Agency for Research on Cancer; 2017. pp. 173–4.
5.
Zurück zum Zitat Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, et al. Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol. 2015;39(6):744–52.CrossRef Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, et al. Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol. 2015;39(6):744–52.CrossRef
6.
Zurück zum Zitat Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39(5):705–13.CrossRef Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, et al. Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol. 2015;39(5):705–13.CrossRef
7.
Zurück zum Zitat Chiosea S, Agaimy A, Hellquist H, Nagao T, Simpson RHW, Van Herpen CM. Salivary duct carcinoma. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of Head and Neck Tumours. Lyon: International Agency for Research on Cancer; 2022. Chiosea S, Agaimy A, Hellquist H, Nagao T, Simpson RHW, Van Herpen CM. Salivary duct carcinoma. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of Head and Neck Tumours. Lyon: International Agency for Research on Cancer; 2022.
8.
Zurück zum Zitat Henley JD, Seo IS, Dayan D, Gnepp DR. Sarcomatoid salivary duct carcinoma of the parotid gland. Hum Pathol. 2000;31(2):208–13.CrossRef Henley JD, Seo IS, Dayan D, Gnepp DR. Sarcomatoid salivary duct carcinoma of the parotid gland. Hum Pathol. 2000;31(2):208–13.CrossRef
9.
Zurück zum Zitat Michal M, Skalova A, Mukensnabl P. Micropapillary carcinoma of the parotid gland arising in mucinous cystadenoma. Virchows Arch. 2000;437(4):465–8.CrossRef Michal M, Skalova A, Mukensnabl P. Micropapillary carcinoma of the parotid gland arising in mucinous cystadenoma. Virchows Arch. 2000;437(4):465–8.CrossRef
10.
Zurück zum Zitat Nagao T, Gaffey TA, Serizawa H, Iwaya K, Watanabe A, Yoshida T, et al. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol. 2004;122(2):222–31.CrossRef Nagao T, Gaffey TA, Serizawa H, Iwaya K, Watanabe A, Yoshida T, et al. Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature. Am J Clin Pathol. 2004;122(2):222–31.CrossRef
11.
Zurück zum Zitat Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004;28(3):319–26.CrossRef Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance. Am J Surg Pathol. 2004;28(3):319–26.CrossRef
12.
Zurück zum Zitat Simpson RH, Prasad AR, Lewis JE, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27(8):1070–9.CrossRef Simpson RH, Prasad AR, Lewis JE, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27(8):1070–9.CrossRef
13.
Zurück zum Zitat Simpson RH, Skalova A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465(4):371–84.CrossRef Simpson RH, Skalova A, Di Palma S, Leivo I. Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch. 2014;465(4):371–84.CrossRef
14.
Zurück zum Zitat Rooper LM, Mansour M, Yonescu R, Oliai BR, Bishop JA, Westra WH. The Decline of Salivary Adenocarcinoma Not Otherwise Specified as a Tumor Entity: Reclassification Using Contemporary Immunohistochemical Profiling and Diagnostic Criteria. Am J Surg Pathol. 2020. Rooper LM, Mansour M, Yonescu R, Oliai BR, Bishop JA, Westra WH. The Decline of Salivary Adenocarcinoma Not Otherwise Specified as a Tumor Entity: Reclassification Using Contemporary Immunohistochemical Profiling and Diagnostic Criteria. Am J Surg Pathol. 2020.
15.
Zurück zum Zitat Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, et al. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clin Cancer Res. 2016;22(18):4623–33.CrossRef Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, et al. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clin Cancer Res. 2016;22(18):4623–33.CrossRef
16.
Zurück zum Zitat Dogan S, Ng CKY, Xu B, Kumar R, Wang L, Edelweiss M, et al. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Hum Pathol. 2019;88:66–77.CrossRef Dogan S, Ng CKY, Xu B, Kumar R, Wang L, Edelweiss M, et al. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Hum Pathol. 2019;88:66–77.CrossRef
17.
Zurück zum Zitat Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, et al. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019;8(17):7322–9.CrossRef Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, et al. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019;8(17):7322–9.CrossRef
18.
Zurück zum Zitat Karpinets TV, Mitani Y, Liu B, Zhang J, Pytynia KB, Sellen LD, et al. Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. Clin Cancer Res. 2021;27(14):3960–9.CrossRef Karpinets TV, Mitani Y, Liu B, Zhang J, Pytynia KB, Sellen LD, et al. Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. Clin Cancer Res. 2021;27(14):3960–9.CrossRef
19.
Zurück zum Zitat Ku BM, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, et al. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med. 2014;12:299.CrossRef Ku BM, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, et al. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med. 2014;12:299.CrossRef
20.
Zurück zum Zitat Luk PP, Weston JD, Yu B, Selinger CI, Ekmejian R, Eviston TJ, et al. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck. 2016;38(Suppl 1):E1838-47. Luk PP, Weston JD, Yu B, Selinger CI, Ekmejian R, Eviston TJ, et al. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck. 2016;38(Suppl 1):E1838-47.
21.
Zurück zum Zitat Mueller SA, Gauthier MA, Blackburn J, Grady JP, Kraitsek S, Hajdu E, et al. Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Mod Pathol. 2020;33(10):1896–909.CrossRef Mueller SA, Gauthier MA, Blackburn J, Grady JP, Kraitsek S, Hajdu E, et al. Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Mod Pathol. 2020;33(10):1896–909.CrossRef
22.
Zurück zum Zitat Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, et al. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018;124(18):3693–705.CrossRef Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, et al. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018;124(18):3693–705.CrossRef
23.
Zurück zum Zitat Shimura T, Tada Y, Hirai H, Kawakita D, Kano S, Tsukahara K, et al. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. Oncotarget. 2018;9(2):1852–67.CrossRef Shimura T, Tada Y, Hirai H, Kawakita D, Kano S, Tsukahara K, et al. Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. Oncotarget. 2018;9(2):1852–67.CrossRef
24.
Zurück zum Zitat Jeong JS, Cho KJ, Kim D, Lee YS, Song JS. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma. Pathol Res Pract. 2021;228:153678.CrossRef Jeong JS, Cho KJ, Kim D, Lee YS, Song JS. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma. Pathol Res Pract. 2021;228:153678.CrossRef
25.
Zurück zum Zitat Kusafuka K, Onitsuka T, Muramatsu K, Miki T, Murai C, Suda T, et al. Salivary duct carcinoma with rhabdoid features: report of 2 cases with immunohistochemical and ultrastructural analyses. Head Neck. 2014;36(3):E28–35.CrossRef Kusafuka K, Onitsuka T, Muramatsu K, Miki T, Murai C, Suda T, et al. Salivary duct carcinoma with rhabdoid features: report of 2 cases with immunohistochemical and ultrastructural analyses. Head Neck. 2014;36(3):E28–35.CrossRef
26.
Zurück zum Zitat Kusafuka K, Kawasaki T, Maeda M, Yamanegi K, Baba S, Ito Y, et al. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast. Histopathology. 2017;70(2):164–73.CrossRef Kusafuka K, Kawasaki T, Maeda M, Yamanegi K, Baba S, Ito Y, et al. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast. Histopathology. 2017;70(2):164–73.CrossRef
27.
Zurück zum Zitat Kusafuka K, Yamada H, Ishino K, Maeda M, Yamanegi K, Baba S, et al. Salivary Duct Carcinoma With Rhabdoid Features-No or Aberrant Expression of E-cadherin and Genetic Changes in CDH1: Immunohistochemical and Genetic Analyses of 17 Cases. Am J Surg Pathol. 2021;45(4):439–49.CrossRef Kusafuka K, Yamada H, Ishino K, Maeda M, Yamanegi K, Baba S, et al. Salivary Duct Carcinoma With Rhabdoid Features-No or Aberrant Expression of E-cadherin and Genetic Changes in CDH1: Immunohistochemical and Genetic Analyses of 17 Cases. Am J Surg Pathol. 2021;45(4):439–49.CrossRef
28.
Zurück zum Zitat Akaki M, Ishihara A, Nagai K, Naono H, Taguchi K, Yamamoto H, et al. Signet Ring Cell Differentiation in Salivary Duct Carcinoma with Rhabdoid Features: Report of Three Cases and Literature Review. Head Neck Pathol. 2021;15(1):341–51.CrossRef Akaki M, Ishihara A, Nagai K, Naono H, Taguchi K, Yamamoto H, et al. Signet Ring Cell Differentiation in Salivary Duct Carcinoma with Rhabdoid Features: Report of Three Cases and Literature Review. Head Neck Pathol. 2021;15(1):341–51.CrossRef
29.
Zurück zum Zitat Otsuru M, Aoki T, Kondo Y, Ota Y, Sasaki M, Suzuki T, et al. Salivary Duct Carcinoma with Invasive Micropapillary and Rhabdoid Feature Arising in the Submandibular Gland. Tokai J Exp Clin Med. 2017;42(1):30–6. Otsuru M, Aoki T, Kondo Y, Ota Y, Sasaki M, Suzuki T, et al. Salivary Duct Carcinoma with Invasive Micropapillary and Rhabdoid Feature Arising in the Submandibular Gland. Tokai J Exp Clin Med. 2017;42(1):30–6.
30.
Zurück zum Zitat Lei L, Van Staalduinen E, Troxell M, Ozawa MG, Zeineh M, Berry G. Mammary Lobular Carcinoma-Like Salivary Gland Carcinoma: Report of a Rare Case. Head Neck Pathol; 2021. Lei L, Van Staalduinen E, Troxell M, Ozawa MG, Zeineh M, Berry G. Mammary Lobular Carcinoma-Like Salivary Gland Carcinoma: Report of a Rare Case. Head Neck Pathol; 2021.
31.
Zurück zum Zitat Rooper LM, Argyris PP, Thompson LDR, Gagan J, Westra WH, Jordan RC, et al. Salivary Mucinous Adenocarcinoma Is a Histologically Diverse Single Entity With Recurrent AKT1 E17K Mutations: Clinicopathologic and Molecular Characterization With Proposal for a Unified Classification. Am J Surg Pathol. 2021;45(10):1337–47.CrossRef Rooper LM, Argyris PP, Thompson LDR, Gagan J, Westra WH, Jordan RC, et al. Salivary Mucinous Adenocarcinoma Is a Histologically Diverse Single Entity With Recurrent AKT1 E17K Mutations: Clinicopathologic and Molecular Characterization With Proposal for a Unified Classification. Am J Surg Pathol. 2021;45(10):1337–47.CrossRef
32.
Zurück zum Zitat Bishop JA, Gagan J, Baumhoer D, McLean-Holden AL, Oliai BR, Couce M, et al. Sclerosing Polycystic “Adenosis” of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma. Head Neck Pathol. 2020;14(3):630–6.CrossRef Bishop JA, Gagan J, Baumhoer D, McLean-Holden AL, Oliai BR, Couce M, et al. Sclerosing Polycystic “Adenosis” of Salivary Glands: A Neoplasm Characterized by PI3K Pathway Alterations More Correctly Named Sclerosing Polycystic Adenoma. Head Neck Pathol. 2020;14(3):630–6.CrossRef
33.
Zurück zum Zitat Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia. 2016;30(9):1916–20.CrossRef Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia. 2016;30(9):1916–20.CrossRef
34.
Zurück zum Zitat Palsgrove DN, Brosnan-Cashman JA, Giannini C, Raghunathan A, Jentoft M, Bettegowda C, et al. Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Mod Pathol. 2018;31(12):1787–800.CrossRef Palsgrove DN, Brosnan-Cashman JA, Giannini C, Raghunathan A, Jentoft M, Bettegowda C, et al. Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Mod Pathol. 2018;31(12):1787–800.CrossRef
35.
Zurück zum Zitat Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem. 1996;61(4):514–23.CrossRef Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem. 1996;61(4):514–23.CrossRef
36.
Zurück zum Zitat Bruner HC, Derksen PWB. Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer. Cold Spring Harb Perspect Biol. 2018;10(3). Bruner HC, Derksen PWB. Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer. Cold Spring Harb Perspect Biol. 2018;10(3).
37.
Zurück zum Zitat Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108(29):11930–5.CrossRef Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108(29):11930–5.CrossRef
38.
Zurück zum Zitat Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13(9):1919–25. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13(9):1919–25.
39.
Zurück zum Zitat De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183(4):404–11.CrossRef De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183(4):404–11.CrossRef
40.
Zurück zum Zitat Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1(1):23–32.CrossRef Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1(1):23–32.CrossRef
41.
Zurück zum Zitat Massari G, Magnoni F, Favia G, Peradze N, Veronesi P, La Vecchia C, et al. Frequency of CDH1 Germline Mutations in Non-Gastric Cancers. Cancers (Basel). 2021;13(10). Massari G, Magnoni F, Favia G, Peradze N, Veronesi P, La Vecchia C, et al. Frequency of CDH1 Germline Mutations in Non-Gastric Cancers. Cancers (Basel). 2021;13(10).
42.
Zurück zum Zitat Teo MY, Al-Ahmadie H, Seier K, Tully C, Regazzi AM, Pietzak E, et al. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. Br J Cancer. 2021;124(7):1214–21.CrossRef Teo MY, Al-Ahmadie H, Seier K, Tully C, Regazzi AM, Pietzak E, et al. Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. Br J Cancer. 2021;124(7):1214–21.CrossRef
43.
Zurück zum Zitat Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690–705 e9.CrossRef Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690–705 e9.CrossRef
44.
Zurück zum Zitat Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, et al. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 2018;33(4):721–35. e8.CrossRef Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, et al. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. 2018;33(4):721–35. e8.CrossRef
45.
Zurück zum Zitat Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–13.CrossRef Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–13.CrossRef
46.
Zurück zum Zitat Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92(3):404–8.CrossRef Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92(3):404–8.CrossRef
47.
Zurück zum Zitat Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106(2):208–15.CrossRef Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106(2):208–15.CrossRef
48.
Zurück zum Zitat Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2008;32(5):773–83.CrossRef Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 2008;32(5):773–83.CrossRef
49.
Zurück zum Zitat Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.CrossRef Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.CrossRef
50.
Zurück zum Zitat Bishop JA, Gagan J, Krane JF, Jo VY. Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor. Head Neck Pathol; 2020. Bishop JA, Gagan J, Krane JF, Jo VY. Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor. Head Neck Pathol; 2020.
51.
Zurück zum Zitat Hernandez-Prera JC, Saeed-Vafa D, Heidarian A, Gewandter K, Otto K, Wenig BM. Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature. Head Neck Pathol; 2021. Hernandez-Prera JC, Saeed-Vafa D, Heidarian A, Gewandter K, Otto K, Wenig BM. Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature. Head Neck Pathol; 2021.
52.
Zurück zum Zitat Hsieh MS, Lee YH, Jin YT, Kuo YJ. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type. Virchows Arch. 2020. Hsieh MS, Lee YH, Jin YT, Kuo YJ. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type. Virchows Arch. 2020.
53.
Zurück zum Zitat Skalova A, Baneckova M, Laco J, Di Palma S, Agaimy A, Ptakova N, et al. Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity. Am J Surg Pathol. 2022;46(2):268–80.CrossRef Skalova A, Baneckova M, Laco J, Di Palma S, Agaimy A, Ptakova N, et al. Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity. Am J Surg Pathol. 2022;46(2):268–80.CrossRef
54.
Zurück zum Zitat Lobo S, Benusiglio PR, Coulet F, Boussemart L, Golmard L, Spier I, et al. Cancer predisposition and germline CTNNA1 variants. Eur J Med Genet. 2021;64(10):104316.CrossRef Lobo S, Benusiglio PR, Coulet F, Boussemart L, Golmard L, Spier I, et al. Cancer predisposition and germline CTNNA1 variants. Eur J Med Genet. 2021;64(10):104316.CrossRef
55.
Zurück zum Zitat Agaimy A, Baneckova M, Ihrler S, Mueller SK, Franchi A, Hartmann A, et al. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review. Am J Surg Pathol. 2021;45(9):1166–78.CrossRef Agaimy A, Baneckova M, Ihrler S, Mueller SK, Franchi A, Hartmann A, et al. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review. Am J Surg Pathol. 2021;45(9):1166–78.CrossRef
56.
Zurück zum Zitat McLean-Holden AC, Rooper LM, Lubin DJ, Magliocca KR, Manucha V, Sadow PM, et al. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head Neck Pathol; 2022. McLean-Holden AC, Rooper LM, Lubin DJ, Magliocca KR, Manucha V, Sadow PM, et al. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head Neck Pathol; 2022.
57.
Zurück zum Zitat Todorovic E, Dickson BC, Weinreb I. Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing. Head Neck Pathol; 2020. Todorovic E, Dickson BC, Weinreb I. Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing. Head Neck Pathol; 2020.
58.
Zurück zum Zitat Di Palma S, Simpson RH, Marchio C, Skalova A, Ungari M, Sandison A, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology. 2012;61(4):629–43.CrossRef Di Palma S, Simpson RH, Marchio C, Skalova A, Ungari M, Sandison A, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology. 2012;61(4):629–43.CrossRef
59.
Zurück zum Zitat Takase S, Kano S, Tada Y, Kawakita D, Shimura T, Hirai H, et al. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 2017;8(35):59023–35.CrossRef Takase S, Kano S, Tada Y, Kawakita D, Shimura T, Hirai H, et al. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 2017;8(35):59023–35.CrossRef
Metadaten
Titel
Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?
verfasst von
Lisa M. Rooper
Jeffrey Gagan
Justin A. Bishop
Publikationsdatum
06.07.2022
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 4/2022
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-022-01464-3

Weitere Artikel der Ausgabe 4/2022

Head and Neck Pathology 4/2022 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …